These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15998587)

  • 1. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
    Fürstenberger G; Senn E; Morant R; Bolliger B; Senn HJ
    Breast; 2006 Feb; 15(1):64-8. PubMed ID: 15998587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
    Gallego R; Codony-Servat J; García-Albéniz X; Carcereny E; Longarón R; Oliveras A; Tosca M; Augé JM; Gascón P; Maurel J
    Endocr Relat Cancer; 2009 Mar; 16(1):311-7. PubMed ID: 19109398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.
    Eng-Wong J; Hursting SD; Venzon D; Perkins SN; Zujewski JA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1468-73. PubMed ID: 14693739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.
    Schernhammer ES; Holly JM; Hunter DJ; Pollak MN; Hankinson SE
    Endocr Relat Cancer; 2006 Jun; 13(2):583-92. PubMed ID: 16728584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
    Decensi A; Veronesi U; Miceli R; Johansson H; Mariani L; Camerini T; Di Mauro MG; Cavadini E; De Palo G; Costa A; Perloff M; Malone WF; Formelli F
    Clin Cancer Res; 2003 Oct; 9(13):4722-9. PubMed ID: 14581342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
    Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
    J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
    Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
    Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer.
    Unsal E; Köksal D; Yurdakul AS; Atikcan S; Cinaz P
    Respir Med; 2005 May; 99(5):559-65. PubMed ID: 15823452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients.
    Grønbaek H; Tanos V; Meirow D; Peretz T; Raz I; Flyvbjerg A
    Anticancer Res; 2003; 23(3C):2815-20. PubMed ID: 12926118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Kehinde EO; Akanji AO; Mojiminiyi OA; Bashir AA; Daar AS; Varghese R
    Prostate Cancer Prostatic Dis; 2005; 8(1):84-90. PubMed ID: 15775992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
    Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
    Baglietto L; English DR; Hopper JL; Morris HA; Tilley WD; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2007 Apr; 16(4):763-8. PubMed ID: 17416768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study.
    Canzian F; McKay JD; Cleveland RJ; Dossus L; Biessy C; Boillot C; Rinaldi S; Llewellyn M; Chajès V; Clavel-Chapelon F; Téhard B; Chang-Claude J; Linseisen J; Lahmann PH; Pischon T; Trichopoulos D; Trichopoulou A; Zilis D; Palli D; Tumino R; Vineis P; Berrino F; Bueno-de-Mesquita HB; van Gils CH; Peeters PH; Pera G; Barricarte A; Chirlaque MD; Quirós JR; Larrañaga N; Martínez-García C; Allen NE; Key TJ; Bingham SA; Khaw KT; Slimani N; Norat T; Riboli E; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2316-25. PubMed ID: 16214911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3).
    Harris TG; Strickler HD; Yu H; Pollak MN; Monrad ES; Travin MI; Xue X; Rohan TE; Kaplan RC
    Growth Horm IGF Res; 2006 Apr; 16(2):86-92. PubMed ID: 16530441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
    Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
    Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
    Decensi A; Johansson H; Miceli R; Mariani L; Camerini T; Cavadini E; Di Mauro MG; Barreca A; Gonzaga AG; Diani S; Sandri MT; De Palo G; Formelli F
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1047-53. PubMed ID: 11588130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
    Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.
    Renehan AG; Harvie M; Howell A
    Endocr Relat Cancer; 2006 Jun; 13(2):273-8. PubMed ID: 16728563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.